Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Mar 1;101(5):993–1000. doi: 10.1172/JCI1833

Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo.

J Herbert 1, F Bono 1, J Herault 1, C Avril 1, F Dol 1, A Mares 1, P Schaeffer 1
PMCID: PMC508650  PMID: 9486969

Abstract

The binding of 125I-factor Xa to human aortic smooth muscle cell (SMC) monolayers was studied. At 4 degreesC, 125I-factor Xa bound to a single class of binding sites with a dissociation constant value of 3.6+/-0.7 nM and a binding site density of 11,720+/-1,240 sites/cell (n = 9). 125I-factor Xa binding was not affected by factor X, thrombin, or by DX9065, a direct inhibitor of factor Xa, but was inhibited by factor Xa (IC50 = 5.4+/-0.2 nM; n = 9) and by antibodies specific for the effector cell protease receptor 1 (EPR-1), a well-known receptor of factor Xa on various cell types. A factor X peptide duplicating the inter-EGF sequence Leu83-Leu88-(Gly) blocked the binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 = 110+/-21 nM). Factor Xa increased phosphoinositide turnover in SMCs and when added to SMCs in culture was a potent mitogen. These effects were inhibited by DX9065 and by antibodies directed against EPR-1 and PDGF. Increased expression of EPR-1 was identified immunohistochemically on SMCs growing in culture and in SMCs from the rabbit carotid artery after vascular injury. When applied locally to air-injured rabbit carotid arteries, antibodies directed against EPR-1 (100 mug/ artery) strongly reduced myointimal proliferation 14 d after vascular injury (65-71% inhibition, P < 0.01). DX9065 (10 mg/kg, subcutaneous) inhibited myointimal proliferation significantly (43% inhibition, P < 0.05). These findings indicate that SMCs express functional high affinity receptors for factor Xa related to EPR-1, which may be of importance in the regulation of homeostasis of the vascular wall and after vascular injury.

Full Text

The Full Text of this article is available as a PDF (236.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altieri D. C., Edgington T. S. Identification of effector cell protease receptor-1. A leukocyte-distributed receptor for the serine protease factor Xa. J Immunol. 1990 Jul 1;145(1):246–253. [PubMed] [Google Scholar]
  2. Altieri D. C. Xa receptor EPR-1. FASEB J. 1995 Jul;9(10):860–865. doi: 10.1096/fasebj.9.10.7615156. [DOI] [PubMed] [Google Scholar]
  3. Ambrosini G., Altieri D. C. Molecular dissection of effector cell protease receptor-1 recognition of factor Xa. Assignment of critical residues involved in antibody reactivity and ligand binding. J Biol Chem. 1996 Jan 12;271(2):1243–1248. doi: 10.1074/jbc.271.2.1243. [DOI] [PubMed] [Google Scholar]
  4. Ambrosini G., Plescia J., Chu K. C., High K. A., Altieri D. C. Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1. J Biol Chem. 1997 Mar 28;272(13):8340–8345. doi: 10.1074/jbc.272.13.8340. [DOI] [PubMed] [Google Scholar]
  5. Appella E., Robinson E. A., Ullrich S. J., Stoppelli M. P., Corti A., Cassani G., Blasi F. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem. 1987 Apr 5;262(10):4437–4440. [PubMed] [Google Scholar]
  6. Berridge M. J., Dawson R. M., Downes C. P., Heslop J. P., Irvine R. F. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J. 1983 May 15;212(2):473–482. doi: 10.1042/bj2120473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bono F., Herault J. P., Avril C., Schaeffer P., Lormeau J. C., Herbert J. M. Human umbilical vein endothelial cells express high affinity receptors for factor Xa. J Cell Physiol. 1997 Jul;172(1):36–43. doi: 10.1002/(SICI)1097-4652(199707)172:1<36::AID-JCP4>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  8. Bouchard B. A., Catcher C. S., Thrash B. R., Adida C., Tracy P. B. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem. 1997 Apr 4;272(14):9244–9251. doi: 10.1074/jbc.272.14.9244. [DOI] [PubMed] [Google Scholar]
  9. Cirino G., Cicala C., Bucci M., Sorrentino L., Ambrosini G., DeDominicis G., Altieri D. C. Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest. 1997 May 15;99(10):2446–2451. doi: 10.1172/JCI119428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Coughlin S. R. Thrombin receptor structure and function. Thromb Haemost. 1993 Jul 1;70(1):184–187. [PubMed] [Google Scholar]
  11. Daniel T. O., Gibbs V. C., Milfay D. F., Garovoy M. R., Williams L. T. Thrombin stimulates c-sis gene expression in microvascular endothelial cells. J Biol Chem. 1986 Jul 25;261(21):9579–9582. [PubMed] [Google Scholar]
  12. Davie E. W., Fujikawa K., Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991 Oct 29;30(43):10363–10370. doi: 10.1021/bi00107a001. [DOI] [PubMed] [Google Scholar]
  13. Gasic G. P., Arenas C. P., Gasic T. B., Gasic G. J. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2317–2320. doi: 10.1073/pnas.89.6.2317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Herbert J. M., Dupuy E., Laplace M. C., Zini J. M., Bar Shavit R., Tobelem G. Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway. Biochem J. 1994 Oct 1;303(Pt 1):227–231. doi: 10.1042/bj3030227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Herbert J. M., Guy A. F., Lamarche I., Mares A. M., Savi P., Dol F. Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide. J Cell Physiol. 1997 Feb;170(2):106–114. doi: 10.1002/(SICI)1097-4652(199702)170:2<106::AID-JCP2>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  16. Herbert J. M., Lamarche I., Dol F. Induction of vascular smooth muscle cell growth by selective activation of the thrombin receptor. Effect of heparin. FEBS Lett. 1992 Apr 20;301(2):155–158. doi: 10.1016/0014-5793(92)81237-g. [DOI] [PubMed] [Google Scholar]
  17. Herbert J. M., Tissinier A., Defreyn G., Maffrand J. P. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb. 1993 Aug;13(8):1171–1179. doi: 10.1161/01.atv.13.8.1171. [DOI] [PubMed] [Google Scholar]
  18. Kazama Y., Komiyama Y., Kisiel W. Tissue factor pathway inhibitor and protease nexin-1 are major factor Xa binding proteins on the HepG2 cell surface. Blood. 1993 Feb 1;81(3):676–682. [PubMed] [Google Scholar]
  19. Ko F. N., Yang Y. C., Huang S. C., Ou J. T. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest. 1996 Sep 15;98(6):1493–1501. doi: 10.1172/JCI118938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kook Y. H., Adamski J., Zelent A., Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 1994 Sep 1;13(17):3983–3991. doi: 10.1002/j.1460-2075.1994.tb06714.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lormeau J. C., Herault J. P., Gaich C., Barzu T., van Dinther T. G., Visser A., Herbert J. M. Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogues. Thromb Res. 1997 Jan 1;85(1):67–75. doi: 10.1016/s0049-3848(96)00223-x. [DOI] [PubMed] [Google Scholar]
  22. McGee M. P., Rothberger H. Assembly of the prothrombin activator complex on rabbit alveolar macrophage high-affinity factor Xa receptors. A kinetic study. J Exp Med. 1986 Dec 1;164(6):1902–1914. doi: 10.1084/jem.164.6.1902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  24. Nicholson A. C., Nachman R. L., Altieri D. C., Summers B. D., Ruf W., Edgington T. S., Hajjar D. P. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem. 1996 Nov 8;271(45):28407–28413. doi: 10.1074/jbc.271.45.28407. [DOI] [PubMed] [Google Scholar]
  25. Nystedt S., Emilsson K., Wahlestedt C., Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9208–9212. doi: 10.1073/pnas.91.20.9208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ragosta M., Gimple L. W., Gertz S. D., Dunwiddie C. T., Vlasuk G. P., Haber H. L., Powers E. R., Roberts W. C., Sarembock I. J. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1994 Mar;89(3):1262–1271. doi: 10.1161/01.cir.89.3.1262. [DOI] [PubMed] [Google Scholar]
  27. Rodgers G. M., Shuman M. A. Characterization of the interaction between factor Xa and bovine aortic endothelial cells. Biochim Biophys Acta. 1985 Mar 21;844(3):320–329. doi: 10.1016/0167-4889(85)90133-8. [DOI] [PubMed] [Google Scholar]
  28. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  29. Sakai T., Kisiel W. Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va. J Biol Chem. 1990 Jun 5;265(16):9105–9113. [PubMed] [Google Scholar]
  30. Schaeffer P., Mares A. M., Dol F., Bono F., Herbert J. M. Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta. Circ Res. 1997 Nov;81(5):824–828. doi: 10.1161/01.res.81.5.824. [DOI] [PubMed] [Google Scholar]
  31. Stitt T. N., Conn G., Gore M., Lai C., Bruno J., Radziejewski C., Mattsson K., Fisher J., Gies D. R., Jones P. F. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell. 1995 Feb 24;80(4):661–670. doi: 10.1016/0092-8674(95)90520-0. [DOI] [PubMed] [Google Scholar]
  32. Tracy P. B., Eide L. L., Mann K. G. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem. 1985 Feb 25;260(4):2119–2124. [PubMed] [Google Scholar]
  33. Tracy P. B., Nesheim M. E., Mann K. G. Platelet factor Xa receptor. Methods Enzymol. 1992;215:329–360. doi: 10.1016/0076-6879(92)15075-n. [DOI] [PubMed] [Google Scholar]
  34. Wu X., Helfrich M. H., Horton M. A., Feigen L. P., Lefkowith J. B. Fibrinogen mediates platelet-polymorphonuclear leukocyte cooperation during immune-complex glomerulonephritis in rats. J Clin Invest. 1994 Sep;94(3):928–936. doi: 10.1172/JCI117459. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES